Aptinyx Stock (NASDAQ:APTX)


ForecastOwnershipChart

Previous Close

$NaN

52W Range

$0.06 - $0.06

50D Avg

-

200D Avg

-

Market Cap

-

Avg Vol (3M)

$132.92K

Beta

1.22

Div Yield

-

APTX Company Profile


Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II/b clinical trial for treating fibromyalgia. It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase II/b clinical trial to treat post-traumatic stress disorder; and NYX-458, an NMDAr modulator, which is in Phase II clinical study for the treatment of Parkinson's disease cognitive impairment. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

12

IPO Date

Jun 21, 2018

Website

APTX Performance


Latest Earnings Call Transcripts


Q3 22Nov 08, 22 | 9:46 PM
Q2 22Aug 07, 22 | 7:13 AM
Q1 22May 13, 22 | 12:50 PM

Peer Comparison


TickerCompany
NUVBNuvation Bio Inc.
MGTADianthus Therapeutics, Inc.
ACHLAchilles Therapeutics plc
ADILAdial Pharmaceuticals, Inc.
RVPHReviva Pharmaceuticals Holdings, Inc.
ABVCABVC BioPharma, Inc.
ADTXAditxt, Inc.
CTMXCytomX Therapeutics, Inc.
SPROSpero Therapeutics, Inc.
QNRXQuoin Pharmaceuticals, Ltd.
RNAZTransCode Therapeutics, Inc.
HILSTharimmune, Inc.
EVLOEvelo Biosciences, Inc.
VRAXVirax Biolabs Group Limited
ASMBAssembly Biosciences, Inc.
ALLRAllarity Therapeutics, Inc.
NRBONeuroBo Pharmaceuticals, Inc.
ATXIAvenue Therapeutics, Inc.
NLTXNeurogene Inc.
TILInstil Bio, Inc.
ALRNAileron Therapeutics, Inc.